title: The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.
authors.forename: T
authors.initials: T
authors.lastname: Schöndorf
authors.forename: T
authors.initials: T
authors.lastname: Forst
authors.forename: C
authors.initials: C
authors.lastname: Hohberg
authors.forename: S
authors.initials: S
authors.lastname: Pahler
authors.forename: C
authors.initials: C
authors.lastname: Link
authors.forename: W
authors.initials: W
authors.lastname: Roth
authors.forename: A
authors.initials: A
authors.lastname: Pfützner
authors.forename: G
authors.initials: G
authors.lastname: Lübben
authors.forename: C
authors.initials: C
authors.lastname: Link
authors.forename: A
authors.initials: A
authors.lastname: Pfützner
mesh_terms: D000368:Aged; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone